These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 23639323)

  • 1. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
    Perrotti D; Neviani P
    Cancer Metastasis Rev; 2008 Jun; 27(2):159-68. PubMed ID: 18213449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.
    Brautigan DL; Farrington C; Narla G
    Clin Sci (Lond); 2021 Jul; 135(13):1545-1556. PubMed ID: 34192314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 2A as a potential target for anticancer therapy.
    Kalev P; Sablina AA
    Anticancer Agents Med Chem; 2011 Jan; 11(1):38-46. PubMed ID: 21288198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
    Sangodkar J; Perl A; Tohme R; Kiselar J; Kastrinsky DB; Zaware N; Izadmehr S; Mazhar S; Wiredja DD; O'Connor CM; Hoon D; Dhawan NS; Schlatzer D; Yao S; Leonard D; Borczuk AC; Gokulrangan G; Wang L; Svenson E; Farrington CC; Yuan E; Avelar RA; Stachnik A; Smith B; Gidwani V; Giannini HM; McQuaid D; McClinch K; Wang Z; Levine AC; Sears RC; Chen EY; Duan Q; Datt M; Haider S; Ma'ayan A; DiFeo A; Sharma N; Galsky MD; Brautigan DL; Ioannou YA; Xu W; Chance MR; Ohlmeyer M; Narla G
    J Clin Invest; 2017 Jun; 127(6):2081-2090. PubMed ID: 28504649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.
    Toop HD; Dun MD; Ross BK; Flanagan HM; Verrills NM; Morris JC
    Org Biomol Chem; 2016 May; 14(20):4605-16. PubMed ID: 27102578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
    Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
    FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, regulation, and pharmacological modulation of PP2A phosphatases.
    Lambrecht C; Haesen D; Sents W; Ivanova E; Janssens V
    Methods Mol Biol; 2013; 1053():283-305. PubMed ID: 23860660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.
    Westermarck J
    FEBS J; 2018 Nov; 285(22):4139-4145. PubMed ID: 30055114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
    Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
    J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.
    Clark AR; Ohlmeyer M
    Pharmacol Ther; 2019 Sep; 201():181-201. PubMed ID: 31158394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PP2A in cancer: Combination therapies.
    Mazhar S; Taylor SE; Sangodkar J; Narla G
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):51-63. PubMed ID: 30401535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
    Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Druggable cancer phosphatases.
    Vainonen JP; Momeny M; Westermarck J
    Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
    Wei H; Zhang HL; Xie JZ; Meng DL; Wang XC; Ke D; Zeng J; Liu R
    Curr Med Sci; 2020 Feb; 40(1):1-8. PubMed ID: 32166659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
    Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.